Neunert CE. Management of newly diagnosed immune thrombocytopenia: can we change outcomes? Hematology Am Soc Hematol Educ Program. 2017;2017:400-405.

Benzer Materyaller

• Sanz GF. In MDS, is higher risk higher reward? Hematology Am Soc Hematol Educ Program. 2019;2019:381-390.
  Baskı/Yayın Bilgisi: (2020)
• Dao K-HT, Tyner JW. What’s different about atypical CML and chronic neutrophilic leukemia? Hematology Am Soc Hematol Educ Program. 2015;2015:264-271.
  Baskı/Yayın Bilgisi: (2016)
• Scherber RM, Mesa RA. Managing myelofibrosis (MF) that “blasts” through: advancements in the treatment of relapsed/refractory and blast-phase MF. Hematology Am Soc Hematol Educ Program. 2018;2018:118-126.
  Baskı/Yayın Bilgisi: (2019)
• Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866.
  Baskı/Yayın Bilgisi: (2020)
• Erratum to “Are the review criteria for automated complete blood counts of the International Society of Laboratory Hematology suitable for all hematology laboratories?” [Rev. Bras. Hematol. Hemoter. 2014;36(3):219–225]
  Yazar:: Comar, Samuel Ricardo, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)